Immunocore enters trial collaboration, supply agreement with Bristol Myers

Immunocore Holdings (IMCR) announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY) to investigate Immunocore’s ImmTAC bispecific TCR candidate targeting PRAME HLA-A02, IMC-F106C, in combination with Bristol Myers Squibb’s nivolumab, in first-line advanced cutaneous melanoma. Under the terms of the collaboration, Immunocore will sponsor and fund the registrational Phase 3 clinical trial of IMC-F106C in combination with nivolumab in first-line advanced cutaneous melanoma, and Bristol Myers Squibb will provide nivolumab.